Ragweed-SPIRE Follow-On Study
Completed
- Conditions
- RhinoconjunctivitisRagweed Allergy
- Registration Number
- NCT02396680
- Lead Sponsor
- Circassia Limited
- Brief Summary
The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 249
Inclusion Criteria
° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006
Exclusion Criteria
- Subject or Investigator have been informed of treatment received in Study TR006
- Subjects with significant allergy to animal dander
- Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies
- History of recurrent acute sinusitis or chronic sinusitis
- Received treatment with an investigational drug within 4 weeks of Screening
- Unable to understand study requirements or unable to communicate clearly with Investigator
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total Rhinoconjunctivitis Symptom Score Approximately 12 months after first dose in TR006
- Secondary Outcome Measures
Name Time Method Rescue Medication Score Approximately 12 months after first dose in TR006 Skin Prick Test Approximately 12 months after first dose in TR006 Patient Global Assessment Approximately 12 months after first dose in TR006 Immunoglobulin E Test Approximately 12 months after first dose in TR006
Trial Locations
- Locations (3)
Kanata Allergy Services
🇨🇦Kanata, Ontario, Canada
Inflamax Research
🇨🇦Mississauga, Ontario, Canada
Windsor Allergy Asthma Associates
🇨🇦Windsor, Ontario, Canada
Kanata Allergy Services🇨🇦Kanata, Ontario, Canada